INTRODUCTION: Quinine
is a rapid-acting, highly effective blood schizonticide against the
four species of human malaria parasites. The drug is gametocidal
against P. vivax and P. ovale but not P falciparum. It is not active
against liver stage parasites. The mechanism of action of quinine is
unknown. Increasing in vitro resistance of parasites from a number
of areas suggests that quinine resistance will be an increasing
problem. Resistance to quinine is already common in some areas of
Southeast Asia, especially border areas of Thailand, where the drug
may fail if used alone to treat falciparum malaria. However, quinine
still provides at least a partial therapeutic effect in most
patients. Antimicrobial drug resistanceCLINICAL
USES:
Parenteral Treatment of Severe Falciparum Malaria. For many years,
quinine dihydrochloride or quinidine gluconate have been the
treatments of choice for severe falciparum malaria, although
intravenous artesunate now provides an alternative for this
indication. Quinine can be administered slowly intravenously or, in
a dilute solution, intramuscularly. The drug can be administered in
divided doses or by continuous intravenous infusion; treatment should
begin with a loading dose to rapidly achieve effective plasma
concentrations. Because of its cardiac toxicity and the relative
unpredictability of its pharmacokinetics, intravenous quinidine
should be administered slowly with cardiac monitoring. Therapy
should be changed to an effective oral agent as soon as the patient
has improved and can tolerate oral medications.
ORAL
TREATMENT OF FALCIPARUM MALARIA:
Quinine sulfate is appropriate therapy for uncomplicated falciparum
malaria except when the infection was transmitted in an area without
documented chloroquine-resistant malaria. Quinine is commonly used
with a second drug (most often doxycycline or, in children,
clindamycin) to shorten quinine’s duration of use (usually to 3
days) and limit toxicity. Quinine is less effective than chloroquine
against other human malarias and is more toxic. Therefore, it is not
used to treat infections with these parasites.
MALARIAL
CHEMOPROPHYLAXIS:
Quinine is not generally used in chemoprophylaxis owing to its
toxicity, although a daily dose of 325 mg is effective.
BABESIOSIS:
Quinine is first-line therapy, in combination with clindamycin, in
the treatment of infection with Babesia microti or other human
babesial infections.
ADVERSE
EFFECTS:
Therapeutic dosages of quinine and quinidine commonly cause tinnitus
(ringing in the ears), headache, nausea, dizziness, flushing, and
visual disturbances, a constellation of symptoms termed cinchonism.
Mild symptoms of cinchonism do not warrant the discontinuation of
therapy. More severe findings, often after prolonged therapy,
include more marked visual and auditory abnormalities, vomiting,
diarrhea, and abdominal pain. Hypersensitivity reactions include
skin rashes, urticaria, angioedema, and bronchospasm. Hematologic
abnormalities include hemolysis (especially with G6PD deficiency),
leukopenia, agranulocytosis, and thrombocytopenia. Therapeutic doses
may cause hypoglycemia through stimulation of insulin release; this
is a particular problem in severe infections and in pregnant
patients, who have increased sensitivity to insulin. Quinine can
stimulate uterine contractions, especially in the third trimester.
However, this effect is mild, and quinine and quinidine remain drugs
of choice for severe falciparum malaria even during pregnancy.
Intravenous infusions of the drugs may cause thrombophlebitis. Severe
hypotension can follow too-rapid intravenous infusions of quinine or
quinidine. Electrocardiographic abnormalities (QT interval
prolongation) are fairly common with intravenous quinidine, but
dangerous arrhythmias are uncommon when the drug is administered
appropriately in a monitored setting. Blackwater fever is a rare
severe illness that includes marked hemolysis and hemoglobinuria in
the setting of quinine therapy for malaria. It appears to be due to a
hypersensitivity reaction to the drug, although its pathogenesis is
uncertain.
CONTRAINDICATIONS
& CAUTIONS: Quinine
(or quinidine)
should be discontinued if signs of severe cinchonism, hemolysis, or
hypersensitivity occur. It should be avoided if possible in patients
with underlying visual or auditory problems. It must be used with
great caution in those with underlying cardiac abnormalities. Quinine
should not be given concurrently with mefloquine and should be used
with caution in a patient with malaria who has previously received
mefloquine chemoprophylaxis. Absorption may be blocked by aluminum
containing antacids. Quinine can raise plasma levels of warfarin and
digoxin. Dosage must be reduced in renal insufficiency.
RELATED;
1. ARTEMISININ COMBINATION THERAPIES
2. PLASMODIUM
references